4 - SECONDARY Hypertension
Page 1
Title
PHARMACIAE ET 1858 DOCENDO DISCITUR 1857 Z ARTERIAL HYPERTENSION (II)Author: Elisabeta Badila
Page 2
Topics
Secondary hypertension
Page 3
Overview of Secondary Hypertension
Definition: Identifiable and potentially reversible cause of hypertension.
Prevalence: Affects 5–10% of people with hypertension.
Consequences: Associated with cardiovascular events, increased mortality, and hypertension-mediated organ damage (HMOD) affecting heart and kidney.
Page 4
When to Consider Secondary Hypertension
Patient Characteristics:
Younger patients (<40 years)
Grade 2 hypertension or hypertension onset in childhood
Acute worsening hypertension in previously stable normotensive patients
Signs of Concern:
Resistant hypertension
Severe (grade 3) hypertension or crisis
Extensive HMOD identified
Clinical signs suggesting endocrine disorders or chronic kidney disease (CKD)
Page 5
Second Look for Possible Causes
Laboratory/Degree Indicators:
Excess K⁺ levels at low diuretic doses suggests primary hyperaldosteronism
Decreased GFR (creatinine > 30%) at low doses of ACEI/ARB indicates bilateral renal artery stenosis
Monitoring Indicators:
Non-dipping or reverse dipping in 24-hour blood pressure measurements
Labile blood pressure even under treatment
Page 6
Evaluating Patients for Secondary HT
When to Evaluate:
At presentation with concerns listed above
Who to Evaluate:
Individuals exhibiting signs of secondary hypertension
How to Evaluate:
Comprehensive history and laboratory tests
Page 7
Prevalence and Etiology in Age Groups
Conditions leading to secondary hypertension:
Mid aortic syndrome
Coarctation of aorta
Renal parenchymal and renovascular diseases
Monogenic disorders
Disease specifics by age group from 1 year to over 65 years
Page 8
Medications Increasing Blood Pressure
Common Substances:
Oral contraceptive pills (especially estrogen)
Diet pills (e.g., phenylpropanolamine, sibutramine)
Stimulant drugs (e.g., cocaine, ecstasy)
Liquorice (can mimic hyperaldosteronism)
Other Medications:
Immunosuppressants (e.g., cyclosporin A)
Antiangiogenic cancer therapies (e.g., VEGF inhibitors)
Page 9
Common Causes of Secondary Hypertension
Sleep Apnoea Syndrome:
Importance of recognizing sleep disorders in hypertension
Renal Causes:
Secondary renal parenchymal hypertension
Renovascular hypertension
Endocrine causes including primary hyperaldosteronism
Page 10
Obstructive Sleep Apnoea Syndrome (OSAS)
Diagnostic Features:
Symptoms: Snoring, daytime sleepiness, morning headaches
Clinical signs: Narrowing of upper respiratory tract, macroglossia, significant neck size
Screening: Questionnaires, polysomnography
Prevalence:
5-15% of patients with hypertension
Page 11
Clinical Example of OSAS
Case Study:
Severely compromised patient with high AHI and desaturation index highlights echocardiograms and monitoring for potential organ damage
Page 12
Renoparenchymal Hypertension
Clinical Features:
May be asymptomatic, may present with infections or obstruction history
Laboratory findings: anemia, palpable masses, urinalysis for proteinuria
Prevalence:
1.6-8% of patients with hypertension; 2-10% in resistant hypertension
Page 13
Atherosclerotic Renal Artery Disease (ARVD)
Prevalence:
Significant variation in different populations; high in hypertensive patients
Management Goals:
Control BP, protect kidney function; ACEI or ARB as first-line treatment
Page 14
Ambulatory Blood Pressure Monitoring (ABPM)
Data Analysis:
Chart detailing individual blood pressure readings over a 24-hour period, monitoring for variations at different times of day
Page 15
Imaging Techniques for ARVD
Importance of proper imaging to identify and manage atherosclerotic renal artery stenosis
Page 16
Institutional Management of ARVD
Notes on diagnostic procedures and interventional protocols from personal collections
Page 17
Fibromuscular Dysplasia (FMD)
Characteristics:
Predominantly in young women; "string of beads" appearance on angiography
Angioplasty outcomes vary significantly
Page 18
Visual Identification of FMD
Imaging Results:
CT angiography showcasing typical "string of beads" distribution in renal arteries
Page 19
Primary Hyperaldosteronism
Prevalence and Screening:
Varies significantly based on the population, influenced by disease severity
Genetic Consideration:
Emphasis on family history and early onset
Page 20
Clinical Presentation of Primary Hyperaldosteronism
Symptoms to Monitor:
Muscle weakness, hypokalemia, and hypertension indicators
Page 21
Testing Protocol for Hyperaldosteronism
Importance of correcting hypokalemia, measuring during specific conditions, and necessary drug cessation
Page 22
Pheochromocytoma and Paraganglioma (PPGL)
Symptoms and Importance of Genetic Testing:
Recommended in all patients and identified families with mutations for potential malignancy
Page 23
Other Causes of Secondary Hypertension
Conditions:
Pheochromocytoma, Cushing's syndrome, thyroid disease, hyperparathyroidism, coarctation of the aorta
Page 24
Screening Secondary Forms of Hypertension
General Recommendations:
Exclude other factors; evaluate adherence to therapy
Page 25
Key Messages on Secondary Hypertension
Screen selectively: Not for all hypertensive patients, use clinical judgment
Understand coexistence between primary and secondary hypertension
Page 26
Focus on Resistant Hypertension
Definition: Resistant hypertension characterized by specific medication regimens
Page 27
Definition of Resistant Hypertension
Criteria:
Minimum two anti-hypertensives plus a diuretic at maximum tolerated doses
Page 28
Characteristics of True Resistant Hypertension
Underlying Mechanisms:
Sodium/fluid retention, SNS and RAAS activation, impaired vascular function
Page 29
Evaluation of Resistant Hypertension
Assessments:
Confirm medication adherence and exclude identifiable secondary causes
Page 30
Strategy for BP Control in Resistant Hypertension
Recommendations:
Guidelines for medication adjustment, patient monitoring, and lifestyle interventions
Page 31
BP-Lowering Strategy Recommendations
Coordinated Approach:
Defined strategies for medication use, follow-up, and risk management
Page 32
Hypertensive Emergencies Overview
Definitions:
Distinction between urgency and emergencies based on the presence of vital risks
Page 33
Hypertensive Emergencies Symptoms
Identification of acute organ damage requiring immediate intervention
Page 34
Expert Consensus on Management of Hypertensive Emergencies
Overview and recommendations from the ESC Council
Page 35
Key Questions in BP Reduction
Considerations on when, why, how fast, and which targets to aim for in hypertension management
Page 36
Practical Considerations in Emergencies
The clinical condition drives intervention, not just BP values alone
Page 37
Clinical Priorities
Importance of symptom monitoring and targeted intervention based on organ health
Page 38
Reasons to Reduce BP
Addresses both medium-term control and immediate life-threatening conditions
Page 39
Rate of BP Reduction
Guidelines on urgency and treatment approaches depending on clinical severity
Page 40
Target Values for BP Management
Varied targets based on organ damage severity
Page 41
Medications for Hypertensive Crises
Overview of specific medications recommended for various acute conditions
Page 42
Pharmacological Options for Hypertensive Emergencies
Comprehensive list of medications available for IV treatment
Page 43
Treatment Approaches for Non-Lifethreatening Crises
Strategies for long-term management and adjustments based on prior treatments
Page 44
Treatment Guidelines Summary
A reminder of patient-centric care in hypertension management
Page 45
Final Thought
Recognition that effective treatment requires careful observation and understanding of conditions
Page 46
Acknowledgment
Thank you!